Research graph
References from Cost-Effectiveness and the Economics of Genomic Testing and Molecularly Matched Therapies. Local targets link to admitted publications; unresolved targets remain external evidence.
Anticancer drugs approved by the us food and drug administration from 2009 to 2020 according to their mechanism of action
10.1001/jamanetworkopen.2021.38793 · 2021 · External reference
Projections of the cost of cancer care in the United States: 2010-2020
10.1093/jnci/djq495 · 2011 · External reference
Unintended consequences of expensive cancer therapeutics - the pursuit of marginal indications and a me-too mentality that stifles innovation and creativity: the john conley lecture
10.1001/jamaoto.2014.1570 · 2014 · External reference
High-throughput genomics and clinical outcome in hard-to-treat advanced cancers: results of the MOSCATO 01 trial
10.1158/2159-8290.cd-16-1396 · 2017 · External reference
Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial
10.1038/s41591-019-0424-4 · 2019 · External reference
Initiative for molecular profiling and advanced cancer therapy (IMPACT): an MD anderson precision medicine study
10.1200/po.17.00002 · 2017 · External reference
Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study
10.1038/s41591-019-0407-5 · 2019 · External reference
Unresolved reference
External reference
Cost-effectiveness analysis of a pharmacist-led medication therapy management program: hypertension management
10.1016/j.jval.2020.10.008 · 2021 · External reference
Cost-effectiveness of pembrolizumab as a second-line therapy for hepatocellular carcinoma
10.1001/jamanetworkopen.2020.33761 · 2021 · External reference
10.1200/jco.22.00478
10.1200/jco.22.00478 · 2023 · External reference
Cost-effectiveness of osimertinib in the first-line treatment of patients with EGFR-mutated advanced non-small cell lung cancer
10.1001/jamaoncol.2018.1395 · 2018 · External reference
First- and second-line bevacizumab in addition to chemotherapy for metastatic colorectal cancer:a United States-based cost-effectiveness analysis
10.1200/jco.2014.58.4904 · 2015 · External reference
Cost-effectiveness analysis of regorafenib for metastatic colorectal cancer
10.1200/jco.2015.61.9569 · 2015 · External reference
Cost-effectiveness of pertuzumab in human epidermal growth factor receptor 2-positive metastatic breast cancer
10.1200/jco.2015.62.9105 · 2016 · External reference
Cost-effectiveness analyses of genetic and genomic diagnostic tests
10.1038/nrg.2017.108 · 2018 · External reference
Cost-effectiveness of next-generation sequencing versus single-gene testing for the molecular diagnosis of patients with metastatic non–small-cell lung cancer from the perspective of spanish reference centers
2023 · External reference
Economic impact of next-generation sequencing versus single-gene testing to detect genomic alterations in metastatic non–small-cell lung cancer using a decision analytic model
10.1200/po.18.00356 · 2019 · External reference
Association of broad-based genomic sequencing with survival among patients with advanced non-small cell lung cancer in the community oncology setting
10.1001/jama.2018.9824 · 2018 · External reference
Cost-effectiveness of tumor genomic profiling to guide first-line targeted therapy selection in patients with metastatic lung adenocarcinoma
10.1016/j.jval.2021.09.017 · 2022 · External reference
Cost-effectiveness analysis of adjuvant therapy for BRAF-mutant resected stage III melanoma in medicare patients
10.1245/s10434-021-10288-4 · 2021 · External reference
A personalized paradigm in the treatment of platinum-resistant ovarian cancer - A cost utility analysis of genomic-based versus cytotoxic therapy
10.1016/j.ygyno.2016.04.024 · 2016 · External reference
Cost-effectiveness analysis of genetic testing and tailored first-line therapy for patients with metastatic gastrointestinal stromal tumors
10.1001/jamanetworkopen.2020.13565 · 2020 · External reference
Cost-effectiveness analysis of screening for KRAS and BRAF mutations in metastatic colorectal cancer
10.1093/jnci/djs433 · 2012 · External reference
Cost-effectiveness of RAS genetic testing strategies in patients with metastatic colorectal cancer: a systematic review
10.1016/j.jval.2019.07.009 · 2020 · External reference
KRAS and BRAF mutation analysis in metastatic colorectal cancer: A cost-effectiveness analysis from a Swiss perspective
10.1158/1078-0432.ccr-10-2267 · 2011 · External reference
Cost-effectiveness analysis of KRAS testing and cetuximab as last-line therapy for colorectal cancer
10.1007/bf03256395 · 2010 · External reference
Cost-effectiveness of KRAS testing in metastatic colorectal cancer patients in the United States and Germany
10.1002/ijc.26400 · 2012 · External reference
Unresolved reference
External reference
Cost-effectiveness Evaluation of Targeted Surgical and Endoscopic Therapies for Early Colorectal Adenocarcinoma Based on Biomarker Profiles
10.1001/jamanetworkopen.2019.19963 · 2020 · External reference
Next-generation sequencing panels for the diagnosis of colorectal cancer and polyposis syndromes: a cost-effectiveness analysis
10.1200/jco.2014.59.3665 · 2015 · External reference
Cost-effectiveness analysis of universal germline testing for patients with pancreatic cancer
10.1016/j.surg.2020.06.038 · 2021 · External reference
NCCN guidelines updates: pancreatic cancer
10.6004/jnccn.2014.0063 · 2019 · External reference
A cost-effectiveness analysis of multigene testing for all patients with breast cancer
10.1001/jamaoncol.2019.3323 · 2019 · External reference
The high price of anticancer drugs: Origins, implications, barriers, solutions
10.1038/nrclinonc.2017.31 · 2017 · External reference
Journey of generic imatinib: a case study in oncology drug pricing
10.1200/jop.2016.019737 · 2017 · External reference
Estimation of the percentage of US patients with cancer who benefit from genome-driven oncology
10.1001/jamaoncol.2018.1660 · 2018 · External reference
Precision medicine: affording the successes of science
2023 · External reference
